1. Preclinical trials in mouse models of APL
Preclinical trials in mouse models of APL. A, mouse models of APL respond differentially to As2O3.
Preclinical trials in mouse models of APL. A, mouse models of APL respond differentially to As2O3. PLZF-RARα leukemia proved resistant to therapy as it was resistant to RA as single agent. By contrast, PML-RARα leukemia proved exquisitely sensitive to As2O3, which triggers the degradation of the fusion protein, suggesting that this drug could be used successfully in large-scale clinical trials. B, treatment of PML-RARα mice with RA and As2O3 in combination leads to a longer lasting remission compared to the treatment with As2O3 alone. Blue, sick; purple, healthy.
Caterina Nardella et al. Cancer Discovery 2011;1:
©2011 by American Association for Cancer Research